Network Pharmacology and Molecular Docking Study of the Chinese Miao Medicine LiuYueHuanYang in the Treatment Of Osteoarthritis

Abstract Purpose To examine the potential therapeutic targets of the Chinese Miao medicine formula LiuYueHuanYang (LYHY) in the treatment of osteoarthritis (OA), we analyzed the active compounds of LYHY and the key targets of OA and investigated the interacting pathways using network pharmacological approaches and molecular docking analysis. Methods Network pharmacology was adopted to detect four active components of Hmong medicine LYHY. The key targets and signaling pathways in the treatment of OA were predicted, and the key components and targets were screened for molecular docking. In this study, we retrieved the four active ingredients of the Hmong medicine LYHY from the literature, namely kaempferol, arbutin, glucosyringic acid and guajavarin, and predicted the corresponding targets of the active ingredients by Swiss Target Prediction; and screened the targets related to OA by the databases GeneCard ( https://www.genecards.org/), Genemap ((https://www.omim.org/search/advanced/geneMap ), Drugbank (https://go.drugbank.com/about ) and OMIM (https://www.omim.org/) to screen the targets related to OA.The PPI network was then constructed and the results showed that AKT1, EGFR, MMP9, SRC, MMP2, ABCB1 and CYP19A1 were the key targets of LYHY for the treatment of OA.GO enrichment analysis showed that cellular response to lipids, cellular response to reactive oxygen species, and inflammatory response were closely related to the mechanism of June Redux for the treatment of OA; KEGG pathway analysis showed that EGFR tyrosine kinase inhibitor resistance、ErbB signaling pathway、ErbB signaling pathway、VEGF signaling pathway、Rap1 signaling pathway、Estrogen signaling pathway and Ras signaling pathway were associated with the intervention of LYHY in OA.Molecular docking showed that the active components had a good affinity with EGFR and SRC.